Safety and efficacy of panitumumab therapy after metastatic colorectal cancer progression with cetuximab: Experience at a single Japanese institution

Oncology Letters

Volumn 5, Issue 4, 2013, Pages 1331-1334

  Sonoda, Hiromichi ^a   Mekata, Eiji ^a   Shimizu, Tomoharu ^a   Endo, Yoshihiro ^a   Tani, Tohru ^a  

^a SHIGA UNIVERSITY OF MEDICAL SCIENCE   (Japan)

Author keywords

Anti epidermal growth factor receptor therapy; Chemotherapy; Colorectal cancer; Monoclonal antibodies; Panitumumab

Indexed keywords

ANTIHISTAMINIC AGENT; BEVACIZUMAB; CARCINOEMBRYONIC ANTIGEN; CETUXIMAB; CORTICOSTEROID; IRINOTECAN; K RAS PROTEIN; OXALIPLATIN; PANITUMUMAB;

ADULT; AGED; ANOREXIA; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; COLORECTAL CANCER; DISEASE COURSE; DRUG EFFICACY; DRUG SAFETY; FATIGUE; FEMALE; HUMAN; HYPOCALCEMIA; HYPOMAGNESEMIA; JAPANESE; MALE; METASTASIS; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; RASH; RETROSPECTIVE STUDY; TREATMENT RESPONSE;

EID: 84874409955     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2013.1171     Document Type: Article

References (16)

1. Bokemeyer C, Bondarenko I, Hartmann JT, de Braud F, Schuch G, Zubel A, et al: Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study. Ann Oncol 22: 1535-1546, 2011.
2. Sobrero AF, Maurel J, Fehrenbacher L, Scheithauer W, Abubakr YA, Lutz MP, et al: EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer. J Clin Oncol 26: 2311-2319, 2008.
3. Pfeiffer P, Nielsen D, Yilmaz M, Iversen A, Vejlø C and Jensen BV: Cetuximab and irinotecan as third line therapy in patients with advanced colorectal cancer after failure of irinotecan, oxaliplatin and 5-fluorouracil. Acta Oncol 46: 697-701, 2007.
4. Cohenuram M and Saif MW: Panitumumab the first fully human monoclonal antibody: from the bench to the clinic. Anticancer Drugs 18: 7-15, 2007.
5. Saif MW, Kaley K, Chu E and Copur MS: Safety and efficacy of panitumumab therapy after progression with cetuximab: experience at two institutions. Clinical Colorectal Cancer 9: 315-318, 2010.
6. Power DG, Shah MA, Asmis TR, Garcia JJ and Kemeny NE: Safety and efficacy of panitumumab following cetuximab: retrospective review of the Memorial Sloan-Kettering experience. Invest New Drugs 28: 353-360, 2010.
7. van Persijn van Meerten EL, Gelderblom H and Bloem JL: RECIST revised: implications for the radiologist. A review article on the modified RECIST guideline. Eur Radiol 20: 1456-1467, 2010.
8. Meyerhardt JA and Mayer RJ: Systemic therapy for colorectal cancer. N Engl J Med 352: 476-487, 2005.
9. Van Cutsem E: First-line treatment: approaches with cytotoxic and biologic agents. In: New Treatment Strategies for Metastatic Colorectal Cancer. Chu E (ed). CMP Healthcare Media, Manhasset, NY, pp21-46, 2008.
10. Mendelsohn J and Baselga J: Epidermal growth factor receptor targeting in cancer. Semin Oncol 33: 369-385, 2006.
11. Jean GW and Shah SR: Epidermal growth factor receptor monoclonal antibodies for the treatment of metastatic colorectal cancer. Pharmacotherapy 28: 742-754, 2008.
12. Cmelak AJ, Lordick F, Borner M, Goldberg RM and Saif MW: Management of infusion reactions in clinical trials and beyond: the US and EU perspectives. Oncology (Williston Park) 23 (Suppl.1): 18-25, 2009.
13. Montagut C, Dalmases A, Bellosillo B, Crespo M, Pairet S, Iglesias M, et al: Identification of a mutation in the extracellular domain of the Epidermal Growth Factor Receptor conferring cetuximab resistance in colorectal cancer. Nat Med 18: 221-223, 2012.
14. Freeman D, Sun J, Bass R, et al: Panitumumab and cetuximab epitope mapping and in vitro activity. J Clin Oncol 26 (May 20 Suppl.): 14536, 2008.
15. Leahy DJ: A molecular view of anti-ErbB monoclonal antibody therapy. Cancer Cell 13: 291-293, 2008.
16. Schmiedel J, Blaukat A, Li S, Knöchel T and Ferguson KM: Matuzumab binding to EGFR prevents the conformational rear rangement required for dimerization. Cancer Cell 13: 365-373, 2008.